12 July 2024
ECO Animal Health Group plc
(''ECO" or the "Company")
Investor Presentation covering Full Year Results
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's Full Year results for the period ended 31 March 2024.
The online presentation will take place on Tuesday 16 July at 16:00 BST. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.
To register for the event, please click here.
A video recording of the presentation will be available shortly afterwards here.
Contacts:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO) |
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies Sam Butcher | 020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Lydia Zychowska | 020 7597 5970
|
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
| ICR Consilium (Financial PR) Mary-Jane Elliott Jessica Hodgson | 020 3709 5700 ecoanimalhealth@consilium-comms.com
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
